BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheung CK, Lo CM, Man K, Lau GK. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl. 2010;16:1314-1323. [PMID: 21031547 DOI: 10.1002/lt.22169] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Fox AN, Terrault NA. The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol. 2012;56:1189-1197. [PMID: 22274310 DOI: 10.1016/j.jhep.2011.08.026] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
2 Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Terrault NA. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl. 2011;17:955-962. [PMID: 21462295 DOI: 10.1002/lt.22312] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 5.2] [Reference Citation Analysis]
3 Mahboobi N, Tabatabaei S, Blum H, Alavian S. Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature. Transpl Infect Dis 2012;14:445-51. [DOI: 10.1111/j.1399-3062.2012.00782.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
4 Roche B, Roque-Afonso AM, Nevens F, Samuel D. Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. Transplantation. 2015;99:1321-1334. [PMID: 26038873 DOI: 10.1097/tp.0000000000000777] [Cited by in Crossref: 41] [Cited by in F6Publishing: 13] [Article Influence: 6.8] [Reference Citation Analysis]
5 Hammami MB, Kohli R, Woreta T, Sulkowski MS, Hamilton JP, Toman L, Saberi B, Laurin J, Wang JG, Philosophe B, Cameron AM, Gurakar A. Hepatitis B Virus/Hepatitis D Virus-Coinfected Liver Transplant Candidate Receiving Hepatitis B Virus-Deoxyribonucleic Acid-Positive Allograft and Treated With High-Dose Hepatitis B Immune Globulin. ACG Case Rep J 2021;8:e00582. [PMID: 34549060 DOI: 10.14309/crj.0000000000000582] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS;  Taormina Workshop on Occult HBV Infection Faculty Members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71:397-408. [PMID: 31004683 DOI: 10.1016/j.jhep.2019.03.034] [Cited by in Crossref: 113] [Cited by in F6Publishing: 107] [Article Influence: 37.7] [Reference Citation Analysis]
7 Teegen EM, Maurer MM, Globke B, Pratschke J, Eurich D. Liver transplantation for Hepatitis-B-associated liver disease - Three decades of experience. Transpl Infect Dis. 2019;21:e12997. [PMID: 30203903 DOI: 10.1111/tid.12997] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
8 Shouval D. Expanding the donor pool for liver transplant recipients using HBsAg positive grafts. J Hepatol. 2014;61:717-719. [PMID: 25038488 DOI: 10.1016/j.jhep.2014.07.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol 2013;35:39-52. [PMID: 22829332 DOI: 10.1007/s00281-012-0327-7] [Cited by in Crossref: 131] [Cited by in F6Publishing: 123] [Article Influence: 13.1] [Reference Citation Analysis]
10 Baleriola C, Webster AC, Rawlinson WD. Characterization and risk of blood-borne virus transmission in organ transplantation: what are the priorities? Future Virology 2014;9:1049-60. [DOI: 10.2217/fvl.14.94] [Reference Citation Analysis]
11 Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol 2014; 20(20): 5951-5961 [PMID: 24876718 DOI: 10.3748/wjg.v20.i20.5951] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
12 Pondé RA. Molecular mechanisms underlying HBsAg negativity in occult HBV infection. Eur J Clin Microbiol Infect Dis. 2015;34:1709-1731. [PMID: 26105620 DOI: 10.1007/s10096-015-2422-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
13 Vodkin I, Kuo A. Extended Criteria Donors in Liver Transplantation. Clin Liver Dis. 2017;21:289-301. [PMID: 28364814 DOI: 10.1016/j.cld.2016.12.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
14 Beckebaum S, Kabar I, Cicinnati VR. Hepatitis B and C in liver transplantation: new strategies to combat the enemies. Rev Med Virol 2013;23:172-93. [PMID: 23239274 DOI: 10.1002/rmv.1734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 McCaughan GW. Prevention of post liver transplant HBV recurrence. Hepatol Int. 2011; Aug 10. [Epub ahead of print]. [PMID: 22020819 DOI: 10.1007/s12072-011-9293-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
16 Onoe T, Tahara H, Tanaka Y, Ohdan H. Prophylactic managements of hepatitis B viral infection in liver transplantation. World J Gastroenterol 2016; 22(1): 165-175 [PMID: 26755868 DOI: 10.3748/wjg.v22.i1.165] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
17 Fernández-Galindo DA, Galván-Ramírez ML, Andrade-Sierra J, González-Espinoza E, Evangelista-Carrillo LA, Mendoza-Cabrera S, Rodríguez-Pérez LR, Chiquete E, Armendáriz-Borunda J, Sánchez-Orozco LV. Occult hepatitis B in kidney transplants recipients and donors from Western Mexico. Int J Infect Dis 2020;91:17-21. [PMID: 31669141 DOI: 10.1016/j.ijid.2019.10.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Rendon JC, Cortes-Mancera F, Restrepo-Gutierrez JC, Hoyos S, Navas MC. Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia. PLoS One 2017;12:e0180447. [PMID: 28686707 DOI: 10.1371/journal.pone.0180447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
19 Wang SH, Loh PY, Lin TL, Lin LM, Li WF, Lin YH, Lin CC, Chen CL. Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft. Liver Transpl. 2017;23:1266-1272. [PMID: 28691231 DOI: 10.1002/lt.24814] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
20 Xie M, Rao W, Yang T, Deng Y, Zheng H, Pan C, Liu Y, Shen Z, Jia J. Occult hepatitis B virus infection predicts de novo hepatitis B infection in patients with alcoholic cirrhosis after liver transplantation. Liver Int. 2015;35:897-904. [PMID: 24750566 DOI: 10.1111/liv.12567] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
21 Mutimer D. Hepatitis B after transplantation: competition between the recipient virus and the donor virus. Liver Transpl 2010;16:1225-7. [PMID: 21031536 DOI: 10.1002/lt.22185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
22 Lenci I, Tisone G, DiPaolo D, Duseja AK. Safety of Complete and Sustained Prophylaxis Withdrawal in Patients Liver-transplanted for Hepatitis B Virus-related Cirrhosis at Low Risk of Hepatitis B Virus Recurrence. J Clin Exp Hepatol 2011;1:122-3. [PMID: 25755326 DOI: 10.1016/S0973-6883(11)60134-5] [Reference Citation Analysis]
23 Alavian SM, B. Lankarani K, Rizzetto M, Marzano A, Moghadami M, Nik-eghbolian S, Bahrani A. Management of Hepatitis B Virus Infection in Liver Transplantation Setting; The Rising Concerns and Growing Hopes, Report From 10th Congress of the Iranian Society for Organ Transplantation, 2011, Shiraz, Iran. Hepat Mon 2012;12. [DOI: 10.5812/hepatmon.8094] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Raimondo G, Pollicino T. Occult HBV Infection. In: Liaw Y, Zoulim F, editors. Hepatitis B Virus in Human Diseases. Cham: Springer International Publishing; 2016. pp. 277-301. [DOI: 10.1007/978-3-319-22330-8_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Leong J, Coty P, Fiel MI, Chang C, Florman S, Schiano T. Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts. Hepatol Res 2014;44:1248-52. [PMID: 24107139 DOI: 10.1111/hepr.12249] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
26 Niu Y, Chen X, Feng L, You H, Ren X, Liu H, Zheng J, Shen Z, Jia J. Anti-HBc–positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts. Clinics and Research in Hepatology and Gastroenterology 2014;38:475-80. [DOI: 10.1016/j.clinre.2014.03.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
27 Terrault N. Management strategies for hepatitis B-infected patients undergoing immunomodulatory therapy: Is lamivudine enough? Clinical Liver Disease. 2015;5:43-46. [PMID: 31040947 DOI: 10.1002/cld.447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Fox AN, Terrault NA. Individualizing hepatitis B infection prophylaxis in liver transplant recipients. J Hepatol. 2011;55:507-509. [PMID: 21601598 DOI: 10.1016/j.jhep.2011.04.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
29 Kumar R, Pérez-Del-Pulgar S, Testoni B, Lebossé F, Zoulim F. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA. Liver Int 2016;36 Suppl 1:72-7. [PMID: 26725901 DOI: 10.1111/liv.13001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
30 Chauhan R, Lingala S, Gadiparthi C, Lahiri N, Mohanty SR, Wu J, Michalak TI, Satapathy SK. Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management. World J Hepatol 2018; 10(3): 352-370 [PMID: 29599899 DOI: 10.4254/wjh.v10.i3.352] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
31 Feng S, Lai JC. Expanded criteria donors. Clin Liver Dis 2014;18:633-49. [PMID: 25017080 DOI: 10.1016/j.cld.2014.05.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 7.1] [Reference Citation Analysis]
32 Duvoux C, Belli LS, Fung J, Angelico M, Buti M, Coilly A, Cortesi P, Durand F, Féray C, Fondevila C, Lebray P, Martini S, Nevens F, Polak WG, Rizzetto M, Volpes R, Zoulim F, Samuel D, Berenguer M. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. Aliment Pharmacol Ther 2021;54:583-605. [PMID: 34287994 DOI: 10.1111/apt.16374] [Reference Citation Analysis]
33 Rao W, Xie M, Yang T, Zhang JJ, Gao W, Deng YL, Zheng H, Pan C, Liu YH, Shen ZY. Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation. World J Gastroenterol 2014; 20(36): 13159-13166 [PMID: 25278711 DOI: 10.3748/wjg.v20.i36.13159] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]